Curious if someone more familiar with this space could comment on what exactly is meant when it says the drug in question -- MM120 -- has been "pharmacologically optimized" from the base LSD?

I know the "real" vs "synthetic" distinction is kind of silly w.r.t. psychedelics in general (especially so with LSD since it's only ever been synthetic), but understanding exactly how the new crop of drugs actually differ from the usual suspects would be helpful in evaluating to what degree this is 'just' a business move to offer something proprietary and corner the market vs. it's legitimately better for patients.

That said, I believe the biggest drawback with using LSD in a clinical or therapeutic setting is the length of the experience (12+ hours), so a tweak around shorter duration would make more sense to me.